Please enable JavaScript to continue using this application.

Compare $CNTB vs $XLO | Chartloom

Compare

$CNTB vs $XLO

Connect Biopharma Holdings Ltd · Xilio Therapeutics Inc

CNTB

Connect Biopharma Holdings Ltd

XLO

Xilio Therapeutics Inc

Compare $CNTB vs $XLO

Comparing Connect Biopharma Holdings Ltd and Xilio Therapeutics Inc

CNTBConnect Biopharma Holdings Ltd

XLOXilio Therapeutics Inc

CNTBConnect Biopharma Holdings Ltd

Market cap

$48M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.55x

Rev growth (TTM)

—

YTD performance

-65.5%

52W performance

-52.2%

FCF yield

-125.1%

XLOXilio Therapeutics Inc

Market cap

$54M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.42x

Rev growth (TTM)

327.3%

YTD performance

-3.8%

52W performance

-23.1%

FCF yield

-113.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CNTB

XLO

Detailed metrics comparison

CNTB

Connect Biopharma Holdings Ltd

XLO

Xilio Therapeutics Inc

Market Cap

CNTB$48M

XLO$54M

Enterprise Value

CNTB$21M

XLO$-82M

Price

CNTB$0.87

XLO$9.05

P/E Ratio

CNTBN/A

XLON/A

P/S Ratio

CNTB16.42x

XLO0.84x

EV/Sales

CNTB7.27x

XLO-1.28x

EV/EBITDA

CNTB0.00x

XLO0.00x

P/B Ratio

CNTB2.17x

XLO0.82x

P/FCF Ratio

CNTBN/A

XLON/A

EV/FCF

CNTB-0.35x

XLO1.34x

PEG Ratio

CNTBN/A

XLON/A

Forward P/E (NTM)

CNTBN/A

XLON/A

Forward P/S (NTM)

CNTB5.55x

XLO3.42x

Revenue (TTM)

CNTB$3M

XLO$64M

Revenue Growth (YoY)

CNTBN/A

XLO327.3%

Forward Rev Growth

CNTB98.8%

XLO-34.2%

Gross Margin (TTM)

CNTB0.0%

XLO0.0%

Operating Margin (TTM)

CNTB0.0%

XLO0.0%

EBITDA Margin (TTM)

CNTB-2361.3%

XLO-46.9%

Net Margin (TTM)

CNTB-2336.3%

XLO-34.1%

FCF Margin (TTM)

CNTB-2053.3%

XLO-95.6%

Net Income (TTM)

CNTB$-69M

XLO$-22M

FCF (TTM)

CNTB$-61M

XLO$-61M

EPS (TTM)

CNTB-$1.24

XLO-$1.12

ROE (TTM)

CNTB-16541.0%

XLO-923.0%

ROA (TTM)

CNTB-12158.0%

XLO-1441.0%

ROIC (TTM)

CNTB-16541.0%

XLO-923.0%

Cash

CNTB$27M

XLO$136M

Debt

CNTB$0

XLO$0

Net Cash/Debt

CNTB$27M

XLO$136M

Current Ratio (TTM)

CNTB2.37x

XLO4.25x

Quick Ratio (TTM)

CNTB2.11x

XLO4.15x

Debt/Equity (TTM)

CNTB0.00x

XLO0.00x

Debt/Assets (TTM)

CNTB0.0%

XLO0.0%

Interest Coverage (TTM)

CNTBN/A

XLON/A

Net Debt/EBITDA (TTM)

CNTB0.00x

XLO0.00x

Beta

CNTB-0.07

XLO-0.12

52W Performance

CNTB-52.2%

XLO-23.1%

YTD Performance

CNTB-65.5%

XLO-3.8%

% from 52W High

CNTB-77.2%

XLO-28.1%

% from 52W Low

CNTB2.3%

XLO40.0%

Asset Turnover (TTM)

CNTB0.05x

XLO0.42x

FCF Yield (TTM)

CNTB-125.1%

XLO-113.2%

Earnings Yield (TTM)

CNTB-142.3%

XLO-40.3%

Dividend Yield (TTM)

CNTBN/A

XLON/A

Rule of 40

CNTB-2,053.3

XLO231.7

EV/GP/RG

CNTBN/A

XLON/A

Ticker research

View CNTB research View XLO research

Metric	CNTB Connect Biopharma Holdings Ltd	XLO Xilio Therapeutics Inc
Market & Valuation
Market Cap	$48M	$54M
Enterprise Value	$21M	$-82M
Price	$0.87	$9.05
P/E Ratio	N/A	N/A
P/S Ratio	16.42x	0.84x
EV/Sales	7.27x	-1.28x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.17x	0.82x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.35x	1.34x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	5.55x	3.42x
Revenue & Growth
Revenue (TTM)	$3M	$64M
Revenue Growth (YoY)	N/A	327.3%
Forward Rev Growth	98.8%	-34.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-2361.3%	-46.9%
Net Margin (TTM)	-2336.3%	-34.1%
FCF Margin (TTM)	-2053.3%	-95.6%
Net Income (TTM)	$-69M	$-22M
FCF (TTM)	$-61M	$-61M
EPS (TTM)	-$1.24	-$1.12
ROE (TTM)	-16541.0%	-923.0%
ROA (TTM)	-12158.0%	-1441.0%
ROIC (TTM)	-16541.0%	-923.0%
Financial Health
Cash	$27M	$136M
Debt	$0	$0
Net Cash/Debt	$27M	$136M
Current Ratio (TTM)	2.37x	4.25x
Quick Ratio (TTM)	2.11x	4.15x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.07	-0.12
52W Performance	-52.2%	-23.1%
YTD Performance	-65.5%	-3.8%
% from 52W High	-77.2%	-28.1%
% from 52W Low	2.3%	40.0%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.42x
FCF Yield (TTM)	-125.1%	-113.2%
Earnings Yield (TTM)	-142.3%	-40.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-2,053.3	231.7
EV/GP/RG	N/A	N/A
Ticker research	View CNTB research	View XLO research

Valuation

P/S Ratio

XLO

0.84x

CNTB

16.42x

EV/FCF

CNTB

-0.35x

XLO

1.34x

Growth & revenue

Revenue Growth TTM

XLO

327.3%

Forward Revenue Growth

CNTB

98.8%

XLO

-34.2%

Profitability & performance

Gross Margin

CNTB

0.0%

XLO

0.0%

ROE

XLO

-923.0%

CNTB

-16541.0%

FCF Yield %

XLO

-113.2%

CNTB

-125.1%

52-Week Performance

XLO

-23.1%

CNTB

-52.2%

Detailed metrics comparison

CNTB

Connect Biopharma Holdings Ltd

XLO

Xilio Therapeutics Inc

Market Cap

CNTB$48M

XLO$54M

Enterprise Value

CNTB$21M

XLO$-82M

Price

CNTB$0.87

XLO$9.05

P/E Ratio

CNTBN/A

XLON/A

P/S Ratio

CNTB16.42x

XLO0.84x

EV/Sales

CNTB7.27x

XLO-1.28x

EV/EBITDA

CNTB0.00x

XLO0.00x

P/B Ratio

CNTB2.17x

XLO0.82x

P/FCF Ratio

CNTBN/A

XLON/A

EV/FCF

CNTB-0.35x

XLO1.34x

PEG Ratio

CNTBN/A

XLON/A

Forward P/E (NTM)

CNTBN/A

XLON/A

Forward P/S (NTM)

CNTB5.55x

XLO3.42x

Revenue (TTM)

CNTB$3M

XLO$64M

Revenue Growth (YoY)

CNTBN/A

XLO327.3%

Forward Rev Growth

CNTB98.8%

XLO-34.2%

Gross Margin (TTM)

CNTB0.0%

XLO0.0%

Operating Margin (TTM)

CNTB0.0%

XLO0.0%

EBITDA Margin (TTM)

CNTB-2361.3%

XLO-46.9%

Net Margin (TTM)

CNTB-2336.3%

XLO-34.1%

FCF Margin (TTM)

CNTB-2053.3%

XLO-95.6%

Net Income (TTM)

CNTB$-69M

XLO$-22M

FCF (TTM)

CNTB$-61M

XLO$-61M

EPS (TTM)

CNTB-$1.24

XLO-$1.12

ROE (TTM)

CNTB-16541.0%

XLO-923.0%

ROA (TTM)

CNTB-12158.0%

XLO-1441.0%

ROIC (TTM)

CNTB-16541.0%

XLO-923.0%

Cash

CNTB$27M

XLO$136M

Debt

CNTB$0

XLO$0

Net Cash/Debt

CNTB$27M

XLO$136M

Current Ratio (TTM)

CNTB2.37x

XLO4.25x

Quick Ratio (TTM)

CNTB2.11x

XLO4.15x

Debt/Equity (TTM)

CNTB0.00x

XLO0.00x

Debt/Assets (TTM)

CNTB0.0%

XLO0.0%

Interest Coverage (TTM)

CNTBN/A

XLON/A

Net Debt/EBITDA (TTM)

CNTB0.00x

XLO0.00x

Beta

CNTB-0.07

XLO-0.12

52W Performance

CNTB-52.2%

XLO-23.1%

YTD Performance

CNTB-65.5%

XLO-3.8%

% from 52W High

CNTB-77.2%

XLO-28.1%

% from 52W Low

CNTB2.3%

XLO40.0%

Asset Turnover (TTM)

CNTB0.05x

XLO0.42x

FCF Yield (TTM)

CNTB-125.1%

XLO-113.2%

Earnings Yield (TTM)

CNTB-142.3%

XLO-40.3%

Dividend Yield (TTM)

CNTBN/A

XLON/A

Rule of 40

CNTB-2,053.3

XLO231.7

EV/GP/RG

CNTBN/A

XLON/A

Ticker research

View CNTB research View XLO research

Metric	CNTB Connect Biopharma Holdings Ltd	XLO Xilio Therapeutics Inc
Market & Valuation
Market Cap	$48M	$54M
Enterprise Value	$21M	$-82M
Price	$0.87	$9.05
P/E Ratio	N/A	N/A
P/S Ratio	16.42x	0.84x
EV/Sales	7.27x	-1.28x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.17x	0.82x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.35x	1.34x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	5.55x	3.42x
Revenue & Growth
Revenue (TTM)	$3M	$64M
Revenue Growth (YoY)	N/A	327.3%
Forward Rev Growth	98.8%	-34.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-2361.3%	-46.9%
Net Margin (TTM)	-2336.3%	-34.1%
FCF Margin (TTM)	-2053.3%	-95.6%
Net Income (TTM)	$-69M	$-22M
FCF (TTM)	$-61M	$-61M
EPS (TTM)	-$1.24	-$1.12
ROE (TTM)	-16541.0%	-923.0%
ROA (TTM)	-12158.0%	-1441.0%
ROIC (TTM)	-16541.0%	-923.0%
Financial Health
Cash	$27M	$136M
Debt	$0	$0
Net Cash/Debt	$27M	$136M
Current Ratio (TTM)	2.37x	4.25x
Quick Ratio (TTM)	2.11x	4.15x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.07	-0.12
52W Performance	-52.2%	-23.1%
YTD Performance	-65.5%	-3.8%
% from 52W High	-77.2%	-28.1%
% from 52W Low	2.3%	40.0%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.42x
FCF Yield (TTM)	-125.1%	-113.2%
Earnings Yield (TTM)	-142.3%	-40.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-2,053.3	231.7
EV/GP/RG	N/A	N/A
Ticker research	View CNTB research	View XLO research